VTRS SHAREHOLDER REVIEW: Viatris Inc. (NASDAQ:VTRS) was Sued for Fraud after 15% Stock Drop – Investors are Urged to Contact BFA Law

Core Viewpoint - A lawsuit has been filed against Viatris Inc. and certain senior executives for potential violations of federal securities laws, stemming from misleading statements regarding the company's operational status and the impact of a failed FDA inspection on its financial performance [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Western District of Pennsylvania, titled Quinn v. Viatris Inc., et al., No. 25-cv-466, with investors having until June 3, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Viatris securities [2]. Group 2: Company Background and Allegations - Viatris is a global healthcare company that provides medicines to approximately 1 billion patients across over 165 countries [3]. - The complaint claims that Viatris misrepresented the condition of its facilities, stating they were in "good operating condition" and suitable for their intended purposes, while downplaying the significance of a Warning Letter from the FDA following a failed inspection at its Indore, India facility [3][4]. Group 3: Financial Impact - The failed FDA inspection has had a substantial negative impact on Viatris's financial results, hindering the company from manufacturing and distributing key products, including Lenalidomide [4]. - Following the release of Q4 2024 results on February 27, 2025, Viatris disclosed that the inspection's repercussions would lower 2025 revenue by approximately $500 million and earnings from operations by about $385 million [5]. - The stock price of Viatris fell roughly 15% on February 27, 2025, dropping from $11.24 to $9.53 per share in response to the negative news [5].